42.10
0.50%
+0.205
Cerevel Therapeutics Holdings Inc stock is currently priced at $42.10, with a 24-hour trading volume of 242.53K.
It has seen a +0.50% increased in the last 24 hours and a -0.68% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $41.94 pivot point. If it approaches the $42.13 resistance level, significant changes may occur.
Previous Close:
$41.90
Open:
$41.81
24h Volume:
242.53K
Market Cap:
$7.63B
Revenue:
-
Net Income/Loss:
$-432.84M
P/E Ratio:
-16.84
EPS:
-2.5
Net Cash Flow:
$-346.11M
1W Performance:
-0.07%
1M Performance:
-0.68%
6M Performance:
+83.65%
1Y Performance:
+50.45%
Cerevel Therapeutics Holdings Inc Stock (CERE) Company Profile
Name
Cerevel Therapeutics Holdings Inc
Sector
Industry
Phone
-
Address
131 Dartmouth Street, Suite 502, Boston
Cerevel Therapeutics Holdings Inc Stock (CERE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-08-23 | Downgrade | TD Cowen | Outperform → Market Perform |
Nov-20-23 | Resumed | JP Morgan | Neutral |
Sep-28-23 | Initiated | Piper Sandler | Overweight |
Aug-03-23 | Downgrade | BofA Securities | Buy → Neutral |
May-04-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Apr-10-23 | Initiated | TD Cowen | Outperform |
Mar-17-23 | Downgrade | JP Morgan | Overweight → Neutral |
Mar-16-23 | Resumed | Berenberg | Hold |
Feb-23-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Nov-01-22 | Initiated | Loop Capital | Buy |
Oct-20-22 | Initiated | BofA Securities | Buy |
Sep-29-22 | Initiated | Cantor Fitzgerald | Overweight |
Sep-26-22 | Initiated | Wells Fargo | Overweight |
Sep-13-22 | Initiated | Evercore ISI | Outperform |
Jul-07-22 | Initiated | Mizuho | Neutral |
Feb-15-22 | Initiated | Goldman | Neutral |
Jan-05-22 | Initiated | JP Morgan | Overweight |
Dec-16-21 | Initiated | H.C. Wainwright | Buy |
Jun-18-21 | Initiated | Morgan Stanley | Overweight |
Dec-10-20 | Initiated | Goldman | Buy |
Nov-23-20 | Initiated | Jefferies | Buy |
Nov-09-20 | Initiated | Stifel | Buy |
View All
Cerevel Therapeutics Holdings Inc Stock (CERE) Latest News
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
GlobeNewswire Inc.
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
Zacks Investment Research
Strike While The Market Is Hot
Seeking Alpha
Is AbbVie Stock a Buy Now?
The Motley Fool
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Zacks Investment Research
AbbVie taps new CEO as it faces fresh competition for blockbuster drug Humira
MarketWatch
Cerevel Therapeutics Holdings Inc Stock (CERE) Financials Data
Cerevel Therapeutics Holdings Inc (CERE) Net Income 2024
CERE net income (TTM) was -$432.84 million for the quarter ending December 31, 2023, a -23.14% decrease year-over-year.
Cerevel Therapeutics Holdings Inc (CERE) Cash Flow 2024
CERE recorded a free cash flow (TTM) of -$346.11 million for the quarter ending December 31, 2023, a -16.48% decrease year-over-year.
Cerevel Therapeutics Holdings Inc (CERE) Earnings per Share 2024
CERE earnings per share (TTM) was -$2.67 for the quarter ending December 31, 2023, a -15.09% decline year-over-year.
Cerevel Therapeutics Holdings Inc Stock (CERE) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
COLES N ANTHONY | Director |
Apr 01 '24 |
Sale |
42.33 |
50,000 |
2,116,640 |
15,638 |
COLES N ANTHONY | Director |
Mar 04 '24 |
Option Exercise |
3.50 |
50,000 |
175,000 |
65,638 |
COLES N ANTHONY | Director |
Mar 04 '24 |
Sale |
41.01 |
50,000 |
2,050,550 |
15,638 |
COLES N ANTHONY | Director |
Feb 29 '24 |
Option Exercise |
3.50 |
50,000 |
175,000 |
65,638 |
COLES N ANTHONY | Director |
Feb 29 '24 |
Sale |
41.16 |
50,000 |
2,057,890 |
15,638 |
COLES N ANTHONY | Director |
Feb 07 '24 |
Sale |
41.54 |
2,506 |
104,110 |
15,638 |
Renger John | Chief Scientific Officer |
Feb 07 '24 |
Sale |
41.54 |
2,161 |
89,777 |
6,370 |
COLES N ANTHONY | Director |
Jan 02 '24 |
Option Exercise |
3.50 |
50,000 |
175,000 |
52,704 |
COLES N ANTHONY | Director |
Jan 02 '24 |
Sale |
42.24 |
50,000 |
2,111,815 |
2,704 |
Sanchez Ramiro | Chief Medical Officer |
Dec 26 '23 |
Option Exercise |
3.50 |
10,000 |
35,000 |
24,673 |
About Cerevel Therapeutics Holdings Inc
Cerevel Therapeutics Holdings, Inc. operates as a clinical-stage biopharmaceutical company engages in the development of various therapies for neuroscience diseases. Its products include CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase 1b multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase 2 proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a Phase 1 proof-of-principle trials in acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase 3 program for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase 1 single ascending dose trials for the treatment of substance use disorder (SUD). It is also involved in the development of various preclinical compounds for various neuroscience indications. The company was founded in 2018 and is headquartered in Boston, Massachusetts.
Cap:
|
Volume (24h):